AstraZeneca nets $396M down payment from EU for 300M-plus COVID vaccines I got cancer treatments during COVID-19. Here's what I want doctors to know AbbVie pens $30M Harvard University viral pact with coronavirus in the crosshairs Researchers develop dry powder remdesivir to strike COVID-19 where it counts Deloitte: Medicaid, ACA exchange plan enrollees embracing virtual health Biopharma roundup: Moderna confirms Japan talks for 40M-plus vaccine doses Pfizer, Moderna's coronavirus shot rollouts could freeze up, experts say, citing cold-storage needs Many people of color, immigrants among over 1,000 U.S. health workers lost to COVID Beyond hospitals, startup Stasis Labs is seeing increased traction for remote monitoring among outpatient providers Romark snares FDA nod to make diarrhea med Alinia at Puerto Rico plant—and supply a COVID candidate's trials, too Featured Story | By Fraiser Kansteiner Earlier this month, AstraZeneca signed the European Union's first formalized vaccine agreement, pledging 400 million doses at no profit. Now, the European Commission has come back with a $396 million down payment for an initial 300 million doses. read more |
| |
|---|
|
Top Stories By Jacqueline Renfrow Cancer does not take a break during a pandemic. Here's a patient experience about what it was like returning for treatment amid fears of contracting the virus. read more By Ben Adams AbbVie and Harvard have signed up to a new $30 million early-stage infectious disease pact with coronavirus and hemorrhagic fever viruses two key targets of the deal. read more By Fraiser Kansteiner A University of Texas research team had already developed its thin-film freezing technology when COVID-19 struck. With the drug delivery platform primed to create dry powder formulations of established meds, the team set to work creating an inhaled version of the antiparasitic niclosamide for coronavirus testing—and then targeted Gilead Sciences' remdesivir. read more By Paige Minemyer As many Americans drop out of employer plans and seek coverage elsewhere amid the pandemic, insurers will need to adjust their marketing strategies to reach them more effectively, a new report shows. read more By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner Moderna could supply at least 40 million shots to Japan. J&J will launch a phase 2 vaccine study in Europe next week. Laurent Pharma got the OK to run a phase 2 on its COVID-19 drug. Sinovac snared emergency approval for its shot in China; plus, Jacobson will help Fosun crank out BioNTech shots in Hong Kong. read more By Kyle Blankenship Drugmakers on the hunt for a COVID-19 vaccine have promised massive supply rollouts in the coming months if their candidates pass regulators' scrutiny. But promises and results are very different things: For two highly touted mRNA-based shots, cold-storage requirements could hobble their launches. read more By Danielle Renwick, The Guardian,Shoshana Dubnow, Kaiser Health News The Guardian and KHN release new figures showing that, among health care workers, a disproportionate number of immigrants and minorities have died. read more By Heather Landi Remote monitoring startup Stasis Labs is rapidly scaling its operation to meet demand in the U.S. created by the pandemic. The company built a cloud-based remote monitoring system that's easy to install and it's providing to be essential for outpatient centers. Here's why Stasis Labs believes remote care is going to be the future of healthcare delivery. read more By Fraiser Kansteiner Romark's manufacturing site in Manati, Puerto Rico, snagged a thumbs up from the FDA to to produce the diarrhea drug Alinia for the U.S. market. The approval is expected to tee up 300 new hires over the next three years; plus, Romark will use the facility to supply trials of its COVID hopeful, NT-300. read more |
